Avery Therapeutics is a Tucson, Arizona biotechnology company spun out of the University of Arizona (Sarver Heart Center) that develops immunomodulatory biologic therapeutics designed to redirect the immune system toward repair in diseases of aging, inflammation and fibrosis. Its lead product, MyCardia, is a tissue-engineered heart graft in pre-clinical development intended to restore cardiac function in patients with chronic heart failure.
1
Round
1
Industry
3
Tags
Sep 21, 2026
Latest raise
Funding activity · 1 round
Sep 21, 2026
$8.5M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
